Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Specimen Handling 35Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × cositecan × Dermatologic × Clear all
NCT00062491 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
46 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00358319 2013-11-25

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
42 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡